SCM
UNCY icon

Silverarc Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Silverarc Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-241,349
Closed -$1.39M – 85
2025
Q1 		$1.39M Sell
241,349
-7,322
-3% -$44.7K 0.28% 56
2024
Q4 		$1.97M Sell
248,671
-151,329
-38% -$838K 0.43% 45
2024
Q3 		$1.63M Buy
+400,000
New +$1.61M 0.37% 50

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silverarc Capital Management's UNCY Position: Q2 2025 in Review

Silverarc Capital Management sold out of Unicycive Therapeutics (UNCY) in Q2 2025, closing a stake of 241,349 shares — an estimated $1.39M sold.

Silverarc Capital Management first reported a position in UNCY in Q3 2024 and held it in 3 quarters. The position peaked at $1.97M in Q4 2024. 20 funds tracked by Wall St. Rank hold UNCY as of Q2 2025.

  • Silverarc Capital Management reported no remaining Unicycive Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 241,349 Unicycive Therapeutics shares in Q2 2025, an estimated $1.39M.
  • Silverarc Capital Management first reported a position in Unicycive Therapeutics in Q3 2024 and held it in 3 quarters.
  • Silverarc Capital Management's Unicycive Therapeutics position peaked at $1.97M in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2025.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.